%0 Journal Article
%T Human papillomavirus types in cervical high©\grade lesions or cancer among Nordic women¡ªPotential for prevention
%A Bo T. Hansen
%A Camilla Lagheden
%A Cecilie Dovey de la Cour
%A Christian Munk
%A Joakim Dillner
%A Kai©\Li Liaw
%A Kristjan Sigurdsson
%A Laufey Trygvad¨®ttir
%A Mari Nyg£¿rd
%A Maria Hortlund
%A Sonia Guleria
%A Susanne K. Kjaer
%J Archive of "Cancer Medicine".
%D 2019
%R 10.1002/cam4.1961
%X It is valuable to establish a population©\based prevaccination baseline distribution of human papillomavirus (HPV) types among women with high©\grade cervical intraepithelial neoplasia (CIN) grade 2 or 3 and cervical cancer in order to assess the potential impact of HPV vaccination. In four countries (Denmark, Norway, Sweden, and Iceland), we collected consecutive series of cervical cancers (n = 639) and high©\grade precancerous cervical lesions (n = 1240) during 2004©\2006 before implementation of HPV vaccination and subjected the specimens to standardized HPV genotyping. The HPV prevalence was 82.7% (95% confidence interval [CI] 79.0©\86.4) in CIN2, 91.6% (95% CI 89.7©\93.5) in CIN3, and 86.4% (95% CI 83.7©\89.1) in cervical cancer. The most common HPV types in CIN2/3 were HPV16 (CIN2: 35.9%, 95% CI 31.2©\40.6; CIN3: 50.2%, 95% CI 46.8©\53.6) and HPV31 (CIN2: 10.9%, 95% CI 7.8©\13.9; CIN3: 12.1%, 95% CI 9.9©\14.3), while HPV16 and HPV18 were the most frequent types in cervical cancer (48.8%, 95% CI 44.9©\52.7 and 15.3%, 95% CI 12.5©\18.1, respectively). The prevalence of HPV16/18 decreased with increasing age at diagnosis in both CIN2/3 and cervical cancer (P < 0.0001). Elimination of HPV16/18 by vaccination is predicted to prevent 42% (95% CI 37.0©\46.7) of CIN2, 57% (95% CI 53.8©\60.5) of CIN3 and 64% (95% CI 60.3©\67.7) of cervical cancer. Prevention of the five additional HPV types HPV31/33/45/52/58 would increase the protection to 68% (95% CI 63.0©\72.2) in CIN2, 85% (95% CI 82.4©\87.2) in CIN3 and 80% (95% CI 77.0©\83.2) in cervical cancer. This study provides large©\scale and representative baselines for assessing and evaluating the population©\based preventive impact of HPV vaccination
%K cervical cancer
%K cervical intraepithelial neoplasia
%K human papillomavirus
%K nordic countries
%K prevalence
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382723/